Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM.

Acta Haematol. 2018;140(1):30-39. doi: 10.1159/000490092. Epub 2018 Aug 2.

2.

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V.

Leukemia. 2018 Apr;32(4):920-930. doi: 10.1038/leu.2017.321. Epub 2017 Nov 3.

3.

Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.

Lamothe B, Wierda WG, Keating MJ, Gandhi V.

Clin Cancer Res. 2016 Sep 15;22(18):4712-26. doi: 10.1158/1078-0432.CCR-15-2522. Epub 2016 Mar 29.

4.

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V.

Clin Cancer Res. 2015 Aug 15;21(16):3705-15. doi: 10.1158/1078-0432.CCR-14-2809. Epub 2015 Mar 31.

5.

Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.

Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V.

Blood. 2015 Jan 8;125(2):407-10. doi: 10.1182/blood-2014-07-585364. No abstract available.

6.

Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice.

Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, Tran D, Ho M, Dawud S, Dong C, Lin HK, Hu P, Estrov Z, Bueso-Ramos CE, Darnay BG.

PLoS One. 2012;7(12):e51228. doi: 10.1371/journal.pone.0051228. Epub 2012 Dec 10.

7.

TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis.

Lamothe B, Lai Y, Xie M, Schneider MD, Darnay BG.

Mol Cell Biol. 2013 Feb;33(3):582-95. doi: 10.1128/MCB.01225-12. Epub 2012 Nov 19.

8.

Virion assembly factories in the nucleus of polyomavirus-infected cells.

Erickson KD, Bouchet-Marquis C, Heiser K, Szomolanyi-Tsuda E, Mishra R, Lamothe B, Hoenger A, Garcea RL.

PLoS Pathog. 2012;8(4):e1002630. doi: 10.1371/journal.ppat.1002630. Epub 2012 Apr 5.

9.

Critical role of monoubiquitination of histone H2AX protein in histone H2AX phosphorylation and DNA damage response.

Wu CY, Kang HY, Yang WL, Wu J, Jeong YS, Wang J, Chan CH, Lee SW, Zhang X, Lamothe B, Campos AD, Darnay BG, Lin HK.

J Biol Chem. 2011 Sep 2;286(35):30806-15. doi: 10.1074/jbc.M111.257469. Epub 2011 Jun 20.

10.

Structural basis for the lack of E2 interaction in the RING domain of TRAF2.

Yin Q, Lamothe B, Darnay BG, Wu H.

Biochemistry. 2009 Nov 10;48(44):10558-67. doi: 10.1021/bi901462e.

11.

The E3 ligase TRAF6 regulates Akt ubiquitination and activation.

Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK.

Science. 2009 Aug 28;325(5944):1134-8. doi: 10.1126/science.1175065.

12.

E2 interaction and dimerization in the crystal structure of TRAF6.

Yin Q, Lin SC, Lamothe B, Lu M, Lo YC, Hura G, Zheng L, Rich RL, Campos AD, Myszka DG, Lenardo MJ, Darnay BG, Wu H.

Nat Struct Mol Biol. 2009 Jun;16(6):658-66. doi: 10.1038/nsmb.1605. Epub 2009 May 24.

13.

The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL.

Lamothe B, Campos AD, Webster WK, Gopinathan A, Hur L, Darnay BG.

J Biol Chem. 2008 Sep 5;283(36):24871-80. doi: 10.1074/jbc.M802749200. Epub 2008 Jul 10.

14.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

15.

Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20.

Lin SC, Chung JY, Lamothe B, Rajashankar K, Lu M, Lo YC, Lam AY, Darnay BG, Wu H.

J Mol Biol. 2008 Feb 15;376(2):526-40. doi: 10.1016/j.jmb.2007.11.092. Epub 2007 Dec 4.

16.

TRAFs in RANK signaling.

Darnay BG, Besse A, Poblenz AT, Lamothe B, Jacoby JJ.

Adv Exp Med Biol. 2007;597:152-9. Review.

PMID:
17633024
17.

TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation.

Lamothe B, Webster WK, Gopinathan A, Besse A, Campos AD, Darnay BG.

Biochem Biophys Res Commun. 2007 Aug 10;359(4):1044-9. Epub 2007 Jun 11.

18.

TAK1-dependent signaling requires functional interaction with TAB2/TAB3.

Besse A, Lamothe B, Campos AD, Webster WK, Maddineni U, Lin SC, Wu H, Darnay BG.

J Biol Chem. 2007 Feb 9;282(6):3918-28. Epub 2006 Dec 8.

19.

Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation.

Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG.

J Biol Chem. 2007 Feb 9;282(6):4102-12. Epub 2006 Nov 29.

20.
21.
22.

Partial rescue of insulin receptor-deficient mice by transgenic complementation with an activated insulin receptor in the liver.

Baudry A, Jackerott M, Lamothe B, Kozyrev SV, Leroux L, Durel B, Saint-Just S, Joshi RL.

Gene. 2002 Oct 16;299(1-2):219-25.

PMID:
12459269
23.

The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors.

Lax I, Wong A, Lamothe B, Lee A, Frost A, Hawes J, Schlessinger J.

Mol Cell. 2002 Oct;10(4):709-19.

24.

Distinct molecular mechanism for initiating TRAF6 signalling.

Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dzivenu OK, Vologodskaia M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H.

Nature. 2002 Jul 25;418(6896):443-7.

PMID:
12140561
25.

Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.

Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal BB.

J Biol Chem. 2002 Aug 23;277(34):30622-8. Epub 2002 Jun 11.

26.

FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl.

Wong A, Lamothe B, Lee A, Schlessinger J, Lax I.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6684-9. Epub 2002 May 7. Erratum in: Proc Natl Acad Sci U S A 2002 Aug 6;99(16):10941. Li Arnold [corrected to Lee Arnold].

29.

Endocrine pancreas in insulin receptor-deficient mouse pups.

Jackerott M, Baudry A, Lamothe B, Bucchini D, Jami J, Joshi RL.

Diabetes. 2001 Feb;50 Suppl 1:S146-9.

30.

IGF-1 receptor as an alternative receptor for metabolic signaling in insulin receptor-deficient muscle cells.

Baudry A, Lamothe B, Bucchini D, Jami J, Montarras D, Pinset C, Joshi RL.

FEBS Lett. 2001 Jan 19;488(3):174-8.

31.
32.

[Insulin and its receptor: lessons learned from the disruption of their gene in mice].

Baudry A, Bucchini D, Deltour L, Desbois P, Durel B, Duvillié B, Jackerott M, Jami J, Joshi RL, Lamothe B, Lamotte L, Cordonnier-Lefort N, Leroux L, Saint Just S.

Journ Annu Diabetol Hotel Dieu. 1999:105-13. French. No abstract available.

PMID:
10732410
33.

Genetic engineering in mice: impact on insulin signalling and action.

Lamothe B, Baudry A, Desbois P, Lamotte L, Bucchini D, De Meyts P, Joshi RL.

Biochem J. 1998 Oct 15;335 ( Pt 2):193-204. Review.

34.

Genetic manipulation of insulin action and beta-cell function in mice.

Lamothe B, Duvillié B, Cordonnier N, Baudry A, Saint-Just S, Bucchini D, Jami J, Joshi RL.

Mol Cell Biochem. 1998 May;182(1-2):161-8.

PMID:
9609125
35.

Insulin receptor-deficient cells as a new tool for dissecting complex interplay in insulin and insulin-like growth factors.

Lamothe B, Baudry A, Christoffersen CT, De Meyts P, Jami J, Bucchini D, Joshi RL.

FEBS Lett. 1998 Apr 24;426(3):381-5.

36.

Genetically engineered mice as animal models for NIDDM.

Joshi RL, Lamothe B, Bucchini D, Jami J.

FEBS Lett. 1997 Jan 20;401(2-3):99-103. Review.

37.
38.

Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality.

Joshi RL, Lamothe B, Cordonnier N, Mesbah K, Monthioux E, Jami J, Bucchini D.

EMBO J. 1996 Apr 1;15(7):1542-7.

39.

Supplemental Content

Loading ...
Support Center